logo
RBC Capital Sticks to Their Hold Rating for Moncler S.p.A. (0QII)

RBC Capital Sticks to Their Hold Rating for Moncler S.p.A. (0QII)

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. on July 1 and set a price target of €60.00. The company's shares closed last Tuesday at €49.57.
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Dadhania is an analyst with an average return of -5.3% and a 36.22% success rate. Dadhania covers the Consumer Cyclical sector, focusing on stocks such as adidas AG, Kering SA, and EssilorLuxottica SA.
In addition to RBC Capital, Moncler S.p.A. also received a Hold from UBS's Susy Tibaldi in a report issued on June 30. However, on June 24, Citi maintained a Buy rating on Moncler S.p.A. (LSE: 0QII).
0QII market cap is currently €13.38B and has a P/E ratio of 20.97.
Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QII in relation to earlier this year.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Trade: Lutnick says Intel must give stake to government
Trump Trade: Lutnick says Intel must give stake to government

Business Insider

time2 hours ago

  • Business Insider

Trump Trade: Lutnick says Intel must give stake to government

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump with this daily recap compiled by The Fly: Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. INTEL STAKE: Commerce Secretary Howard Lutnick said that in return for CHIPS Act funds, Intel (INTC) must give the U.S. government an equity stake. The comments were made while Lutnick was being interviewed on CNBC's 'Squawk on the Street.' BOND SPREE: President Donald Trump has bought hundreds of bonds since he returned to office, including those sold by U.S. companies affected by federal policy changes he's championed, Bloomberg reports. The bonds, which total at least $103.7M, include municipal bonds and corporate debt from companies such as Qualcomm (QCOM), Home Depot (HD), and Meta Platforms (META), according to the report, which adds that the investments are part of Trump's continued pursuit of wealth accumulation while in office. TARIFF REVENUE TO OFFSET OBBB: S&P Global on Tuesday said it expects tariff-related revenue for the federal government to offset the impact of Trump's 'One Big Beautiful Bill,' leading the agency to leave the U.S.′ credit rating unchanged. MUSK PUMPS BRAKES ON THIRD PARTY PLANS: Tesla (TSLA) CEO Elon Musk is quietly pumping the brakes on plans to start a third political party, the America Party, with a desire to focus on his companies, The Wall Street Journal's Brian Schwartz reports. Musk is wary of alienating Republicans and wants to maintain ties with Vice President JD Vance, a potential 2028 presidential candidate, according to people with knowledge of his plans. The Tesla CEO's team canceled a meeting with a third-party campaign-organizing group, according to the report.

QQQ ETF News, 8/20/2025
QQQ ETF News, 8/20/2025

Business Insider

time4 hours ago

  • Business Insider

QQQ ETF News, 8/20/2025

How is QQQ stock faring? The Invesco QQQ ETF has declined 0.79% over the past five days, but is up 13.2% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $638.41 for the QQQ ETF implies an upside potential of about 12.1%. Currently, QQQ's five holdings with the highest upside potential are Strategy (MSTR), Charter Communications (CHTR), Atlassian Corporation (TEAM), Trade Desk (TTD), and Lululemon Athletica (LULU). (PLTR), Tesla (TSLA), Intel (INTC), and Fastenal (FAST).

PTC Therapeutics CRL ‘expected,' focus moves to Sephience, says RBC Capital
PTC Therapeutics CRL ‘expected,' focus moves to Sephience, says RBC Capital

Yahoo

time7 hours ago

  • Yahoo

PTC Therapeutics CRL ‘expected,' focus moves to Sephience, says RBC Capital

PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich's ataxia, with the FDA stating that substantial evidence of efficacy was not demonstrated and that an additional adequate and well-controlled study would be needed, RBC Capital tells investors in a research note. The firm believes this was generally expected and already baked into the stock, and thinks the focus will hone in on the Sephience launch. RBC Capital, which has an Outperform rating and $63 price target on the stock, would buy shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PTCT: Disclaimer & DisclosureReport an Issue PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback PTC Therapeutics price target lowered to $50 from $56 at TD Cowen PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential PTC Therapeutics Receives FDA Complete Response Letter PTC Therapeutics receives Complete Response Letter for vatiquinone NDA Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store